A Category That Punches Above Its Weight
Sterile injectables represent a minority of dispensed drug products in the United States, yet they have consistently accounted for the majority of active shortages tracked by the FDA and the University of Utah Drug Information Service. In the FDA's own 2019 report on drug shortage root causes, generic sterile injectables made up over 60% of new shortages in the preceding five years, despite representing a much smaller share of total prescription volume. That imbalance has not corrected itself. As of mid-2026, the FDA's shortage database still shows generic injectable oncolytics, anesthetics, electrolytes and critical care drugs as the largest single category, ahead of oral solids, biologics or topicals combined.
The persistence of this pattern across more than a decade, spanning multiple administrations, multiple FDA commissioners and repeated congressional hearings, is the clearest evidence that the cause is structural rather than episodic. Four forces explain it.
Manufacturing Complexity That Doesn't Scale Like Pills
Aseptic manufacturing is fundamentally less forgiving than solid-oral production. A tablet line can tolerate variance in blending or compression and still yield a usable batch. A sterile fill-finish line cannot tolerate a single particulate excursion, an environmental monitoring failure, or a contamination event without triggering a batch rejection, a line shutdown, or in the worst cases a full facility remediation under FDA consent decree.
That fragility shows up in enforcement data. Sterile injectable plants generate a disproportionate share of FDA Form 483 observations and Warning Letters tied to aseptic processing deficiencies, environmental monitoring gaps and data integrity failures. When a facility like Akorn's Amityville plant, Fresenius Kabi's Melrose Park site, or an offshore CDMO faces an Official Action Indicated inspection, the resulting production halt does not just remove one SKU. Sterile plants typically run multiple products across shared filling lines, so a single line qualification failure can knock out several NDCs simultaneously, which is why shortage events in this category tend to arrive in clusters rather than as isolated single-drug incidents.
Capital Intensity and the Economics That Don't Work
Building or requalifying an aseptic fill line costs tens of millions of dollars and takes 18 to 36 months once isolator technology, environmental qualification and FDA pre-approval inspection are factored in. That capital burden collides with generic injectable pricing that has been driven to commodity levels by GPO group purchasing contracts and Medicare Part B reimbursement formulas that reset to average sales price with a lag.
A generic injectable like a vial of morphine, epinephrine or a small-volume electrolyte solution can carry a reimbursement price measured in cents per unit. Manufacturers cannot justify redundant capacity, backup lines or dual sourcing of critical components when the margin on the finished product barely covers cost of goods. The result is a market structure where three or four manufacturers, sometimes fewer, supply the entire U.S. hospital market for a given molecule, and none of them have the balance sheet incentive to hold meaningful buffer capacity. When one producer exits a molecule because it is unprofitable, as has happened repeatedly with older sterile generics, the remaining suppliers cannot absorb the volume overnight because aseptic lines are already running near capacity on their own portfolios.
Thin Margins Meet Fragile Supply Chains
The raw material and component side compounds the problem. Sterile injectables depend on glass vials, stoppers, elastomeric closures and, in many cases, active pharmaceutical ingredients sourced from a concentrated set of overseas suppliers. Borosilicate glass tubing capacity is dominated by a handful of global producers, and any disruption there, whether from energy costs in Europe or capacity constraints in China, ripples across dozens of unrelated drug products that share the same vial format.
Unlike oral solids, where a manufacturer can often qualify an alternate excipient supplier within weeks, sterile component changes typically require revalidation and, in some cases, an FDA supplement, because container closure integrity is a critical quality attribute tied to sterility assurance. That regulatory friction, appropriate on safety grounds, adds months to any attempt to resource around a bottleneck.
Concentration at the Top Makes the System Brittle
A small number of manufacturers, including Pfizer through its Hospira injectables franchise, Fresenius Kabi, Baxter, Fresenius Medical Care's affiliated production, Amphastar and Sandoz, account for a large share of the U.S. generic sterile injectable market. That concentration is itself a rational response to the economics described above: only players with scale across dozens of molecules can spread the fixed cost of aseptic compliance thinly enough to survive on generic margins.
But concentration at the top means the loss of a single facility, whether from a natural disaster, a regulatory action or a voluntary shutdown for remediation, removes a disproportionate share of national supply. Hospital pharmacy buyers and group purchasing organizations, who negotiated for the lowest unit cost rather than for supply resilience, discover the cost of that tradeoff only when a shortage hits the ICU or the operating room.
Implications for Manufacturers and Buyers
For manufacturers, the strategic choice is increasingly binary. Either commit to being a scaled, diversified sterile injectables producer with redundant lines and enough molecule breadth to absorb a single-product disruption, or exit the category entirely and cede it to specialists and 503B outsourcing facilities that can operate under different cost and regulatory structures. Mid-sized generic firms sitting between those two positions are the most likely to exit specific molecules when a plant issue or a price floor makes continued production uneconomical.
For hospital systems, wholesalers and health system pharmacy directors, the practical response has been building multi-source contracts, holding larger buffer inventories of critical care injectables, and in some cases contracting directly with manufacturers for guaranteed volume commitments that trade higher unit price for supply certainty. The 2023 to 2024 shortages of cisplatin and carboplatin, triggered by a single offshore plant's quality failure, accelerated that shift by demonstrating how quickly an entire oncology treatment protocol can be disrupted by one facility's inspection outcome.
Federal policy has moved, if slowly. CMS's Medicare Transformer Model discussions, ASPR's stockpiling initiatives for essential medicines, and renewed congressional interest in tax incentives for domestic sterile manufacturing all point toward treating supply resilience as a public good rather than leaving it to a market structure that has proven, over more than a decade of evidence, unable to price it correctly on its own.
The Road Ahead
The sterile injectable shortage problem will not be solved by a single plant reopening or a single new market entrant. It will only ease if reimbursement mechanisms start pricing in redundancy, if regulators continue to make single-source dependency a disclosed risk factor rather than a hidden one, and if buyers accept that the cheapest vial is not the same as the most available one. Until that recalibration happens, sterile injectables will keep appearing at the top of every shortage list the FDA publishes.